Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
donitabart (BCD-245)
i
Other names:
BCD-245, BCD 245
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Biocad
Drug class:
GD2 ganglioside inhibitor
Related drugs:
‹
dinutuximab beta (2)
naxitamab-gqgk (1)
dinutuximab (1)
TRBS07 (0)
GD2-GD3 Vaccine (0)
GD2-SADA (0)
KUR-501 (0)
Hu14.18K322A (0)
APN301 (0)
GD2xCD3 (0)
dinutuximab beta (2)
naxitamab-gqgk (1)
dinutuximab (1)
TRBS07 (0)
GD2-GD3 Vaccine (0)
GD2-SADA (0)
KUR-501 (0)
Hu14.18K322A (0)
APN301 (0)
GD2xCD3 (0)
›
Associations
News
Trials
Filter by
Latest
over1year
Phase 1 Study of BCD-245 in Subjects With Neuroblastoma (clinicaltrials.gov)
P1, N=24, Recruiting, Biocad
over 1 year ago
New P1 trial
|
NCAM1 (Neural cell adhesion molecule 1)
|
donitabart (BCD-245)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login